We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has sent Allergan a warning letter concerning an advertisement for the acne drug Aczone that overstated efficacy and omitted important risk information.